Dentsply Sirona (XRAY)
(Delayed Data from NSDQ)
$24.71 USD
-0.29 (-1.16%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $24.72 +0.01 (0.04%) 7:58 PM ET
4-Sell of 5 4
A Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$24.71 USD
-0.29 (-1.16%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $24.72 +0.01 (0.04%) 7:58 PM ET
4-Sell of 5 4
A Value B Growth B Momentum A VGM
Zacks News
What's in Store for Varian Medical (VAR) in Q3 Earnings?
by Zacks Equity Research
Probable revenue growth in APAC and EMEA regions and higher Oncology revenues are likely to aid Varian Medical (VAR) in Q3 earnings. However, contraction in margins might be a dampener.
What's in Store for Align Technology (ALGN) in Q2 Earnings?
by Zacks Equity Research
Align Technology (ALGN) is expected to deliver a strong second quarter on continued adoption of Invisalign system.
Intuitive Surgical (ISRG) Q2 Earnings Beat, Guidance Narrowed
by Zacks Equity Research
Intuitive Surgical (ISRG) expects 2019 procedure growth within 16-17%.
Will 2-Pronged Plan Aid Quest Diagnostics (DGX) Q2 Earnings?
by Zacks Equity Research
Quest Diagnostics' (DGX) frequent partnership wins with health care leaders and sensible buyouts are creating bountiful opportunities for the top and the bottom line.
BioTelemetry (BEAT) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
BioTelemetry's (BEAT) strong second-quarter 2019 expectations are indicative of solid results.
What's in Store for Edwards Lifesciences' (EW) Q2 Earnings?
by Zacks Equity Research
Edwards Lifesciences (EW) is likely to deliver a solid second quarter on robust segmental performance.
Here's Why Investors Should Consider Cerner (CERN) Stock
by Zacks Equity Research
For the second quarter, Cerner (CERN) expects revenues between $1.41 billion and $1.46 billion.
Falling Earnings Estimates Signal Weakness Ahead for Patterson Companies (PDCO)
by Zacks Equity Research
Patterson Companies (PDCO) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
7 S&P 500-Beating Stocks to Buy Ahead of Q2 Earnings
by Aniruddha Ganguly
Here we pick seven stocks that have outperformed the S&P 500 and are likely to beat earnings estimates this reporting cycle.
Can Global Industrial Unit Drive Ecolab's (ECL) Q2 Earnings?
by Zacks Equity Research
Ecolab (ECL) likely to see impressive growth in second-quarter adjusted earnings per share.
Will Abbott's (ABT) Q2 Earnings Gain From Overall Growth?
by Zacks Equity Research
Abbott's (ABT) consistent rise on a strong Diabetes Care business performance is seen over the last few quarters.
McKesson (MCK) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Top-line growth and better-than-expected segmental performance are likely to aid McKesson (MCK) in Q1. However, rise in adjusted operating expenses is likely to be a dampener.
Can Instruments Drive Intuitive Surgical (ISRG) Q2 Earnings?
by Zacks Equity Research
Intuitive Surgical (ISRG) expects its core Instruments and Accessories unit to boost second-quarter 2019 results.
AngioDynamics (ANGO) Q4 Earnings Miss, Revenues Top Estimates
by Zacks Equity Research
AngioDyamics (ANGO) gains from solid segmental contributions in fourth-quarter fiscal 2019.
Smith & Nephew Acquires Atracsys, Expands Robotic Portfolio
by Zacks Equity Research
With Smith & Nephew's (SNN) buyout of Atracsys, the latter's fusionTrack 500 optical tracking camera will be a core enabling technology for the company's next-generation robotics platform.
Varian to Acquire Boston Scientific's Embolic Bead Products
by Zacks Equity Research
Varian (VAR) expects the buyout to prove accretive to its fiscal 2020 reported and adjusted earnings per share.
Myriad Genetics' Elevate 2020 Plan Holds Promise Amid Issues
by Zacks Equity Research
Myriad Genetics (MYGN) unveils an 'Elevate 2020' program that aims to generate $50 million in incremental operating income by fiscal 2020.
Medtronic's Titan Spine Buyout to Boost Spine Surgery Range
by Zacks Equity Research
Medtronic's (MDT) comprehensive biologics portfolio clubbed with Titan Spine's surface-enhanced titanium implants can enhance patient outcomes in spinal procedures.
Walgreens Gains on Strategic Deals, Margin Pressure Remains
by Zacks Equity Research
Walgreens Boots' (WBA) Retail Pharmacy USA division is witnessing comparable prescription growth and also benefiting from a strong retail prescription market.
Thermo Fisher's Unit Sale May Not Ail Specialty Diagnostics
by Zacks Equity Research
The Anatomical Pathology business of Thermo Fisher (TMO) belongs to its Specialty Diagnostics segment that serves customers across healthcare and clinical laboratories.
Here's Why You Should Hold Varian Medical (VAR) Stock Now
by Zacks Equity Research
Varian (VAR) expects the Cancer Treatment Services International buyout to prove accretive to earnings per share during fiscal 2021.
Amedisys Rides on New Buyouts, Strength in Personal Care Arm
by Zacks Equity Research
Amedisys' (AMED) recently-integrated Personal Care segment is attaining stability and living up to expectation.
Veeva's Vault eTMF Implemented by South Korea's Celltrion
by Zacks Equity Research
Management at Veeva (VEEV) expects Vault subscription revenues to grow a significant 40% in fiscal 2020.
Patterson Companies' (PDCO) Earnings Miss Estimates in Q4
by Zacks Equity Research
Patterson Companies' (PDCO) Q4 results benefit from higher revenues, gross margin expansion and solid show by Animal Health segment.
Varian (VAR) & Tennessee Oncology to Implement Use of Noona
by Zacks Equity Research
Varian's (VAR) core Oncology unit gets a boost from the latest collaboration with Tennessee Oncology.